Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480478 | 1.00 | NPC1 (0.39) | NPC1RAB9AKDM4ESMN1; SMN2TP53 | |
| SCHEMBL1480794 | 0.92 | MAPT (0.40) | NPC1RAB9AKDM4ESMN1; SMN2HSP90AA1 | |
| SCHEMBL1480791 | 0.92 | MAPT (0.40) | NPC1RAB9AKDM4ESMN1; SMN2HSP90AA1 | |
| SCHEMBL1480157 | 0.87 | DHODH (0.39) | NPC1RAB9AKDM4ESMN1; SMN2HSP90AA1 | |
| SCHEMBL1482814 | 0.87 | MEN1 (0.46) | NPC1RAB9AKDM4ESMN1; SMN2TP53 | |
| SCHEMBL1480155 | 0.87 | DHODH (0.39) | NPC1RAB9AKDM4ESMN1; SMN2HSP90AA1 | |
| SCHEMBL1482813 | 0.87 | MEN1 (0.46) | NPC1RAB9AKDM4ESMN1; SMN2TP53 | |
| SCHEMBL1481354 | 0.87 | TUBB4A (0.46) | NPC1RAB9AKDM4ESMN1; SMN2TP53 | |
| SCHEMBL1481357 | 0.87 | TUBB4A (0.46) | NPC1RAB9AKDM4ESMN1; SMN2TP53 | |
| SCHEMBL1480766 | 0.85 | PTGES (0.44) | NPC1RAB9AKDM4ESMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | NPC1 3792/4885RAB9A 3266/4885KDM4E 672/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | NPC1 3792/4885RAB9A 3266/4885KDM4E 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.